ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER Drug Patent Profile

Which patents cover Esmolol Hydrochloride Double Strength In Plastic Container, and when can generic versions of Esmolol Hydrochloride Double Strength In Plastic Container launch?

Esmolol Hydrochloride Double Strength In Plastic Container is a drug marketed by Hq Spclt Pharma and is included in one NDA. There are two patents protecting this drug.

This drug has seven patent family members in seven countries.

The generic ingredient in ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER is esmolol hydrochloride. There are eight drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the esmolol hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Esmolol Hydrochloride Double Strength In Plastic Container

A generic version of ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER was approved as esmolol hydrochloride by HIKMA on August 10^th, 2004.

Summary for ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

International Patents:	7
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	112
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER
DailyMed Link:	ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER at DailyMed

Recent Clinical Trials for ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Pakistan Institute of Medical Sciences	Phase 4
Muhammad Haroon Anwar	Phase 4
Consorcio Centro de Investigación Biomédica en Red (CIBER)	Phase 3

See all ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER clinical trials

Pharmacology for ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

US Patents and Regulatory Information for ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hq Spclt Pharma	ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER	esmolol hydrochloride	SOLUTION;INTRAVENOUS	205703-002	Apr 7, 2016		RX	Yes	Yes	8,835,505		Y
Hq Spclt Pharma	ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER	esmolol hydrochloride	SOLUTION;INTRAVENOUS	205703-002	Apr 7, 2016		RX	Yes	Yes	8,829,054		Y

Expired US Patents for ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Hq Spclt Pharma	ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER	esmolol hydrochloride	SOLUTION;INTRAVENOUS	205703-002	Apr 7, 2016	6,310,094*PED
Hq Spclt Pharma	ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER	esmolol hydrochloride	SOLUTION;INTRAVENOUS	205703-002	Apr 7, 2016	6,528,540*PED

International Patents for ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

See the table below for patents covering ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	60215129
Canada	2906031	COMPOSITION PHARMACEUTIQUE DE COSOLVANTS PRETE A L'UTILISATION DANS DES RECIPIENTS DE MATIERE PLASTIQUE FLEXIBLES MODIFIES (READY-TO-USE CO-SOLVENTS PHARMACEUTICAL COMPOSITION IN MODIFIED FLEXIBLE PLASTIC CONTAINER)
Czech Republic	304290	Vodná sterilní farmaceutická kompozice pro okamžité použití obsahující hydrochlorid esmololu a způsob její přípravy (Aqueous, sterile pharmaceutical composition for immediate use containing esmolol hydrochloride and process for preparing thereof)
Australia	2002309475
Czech Republic	20023825

ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER Market Analysis and Financial Projection Experimental

Esmolol Hydrochloride Market Dynamics and Financial Trajectory

Overview of Esmolol Hydrochloride

Esmolol hydrochloride is a short-acting beta-blocker widely used in the management of various cardiovascular conditions, including supraventricular tachycardia, non-compensatory sinus tachycardia, and intraoperative and postoperative tachycardia. Its rapid onset and short duration of action make it a preferred choice in clinical settings.

Market Size and Growth

The global esmolol hydrochloride market is projected to exhibit steady growth over the coming years. According to market research, the global esmolol hydrochloride market size is expected to expand at a compound annual growth rate (CAGR) of 4.0% from 2024 to 2031, reaching significant revenue by the end of the forecast period[1][5].

Regional Market Dynamics

North America

North America currently dominates the esmolol hydrochloride market, driven by the increasing incidence of cardiovascular diseases, a rise in surgical procedures, and heightened awareness of effective treatment options. The region's well-established healthcare infrastructure and the availability of both branded and generic formulations contribute to its market growth. The CAGR for North America is estimated at 2.2%, with the United States, Canada, and Mexico showing individual growth rates of 2%, 3%, and 2.7%, respectively[1].

Asia-Pacific

The Asia-Pacific region is anticipated to witness substantial growth, with the highest CAGR among all regions, estimated at 6.0% from 2024 to 2031. This growth is driven by increasing cardiovascular disease rates, a rise in surgical interventions, and improving healthcare access. Growing awareness of treatment options and the introduction of generic formulations are also key factors[1].

Europe

Europe is another significant market for esmolol hydrochloride, with a CAGR of 2.5% from 2024 to 2031. The region's established healthcare system and the increasing prevalence of cardiovascular diseases contribute to the market's expansion[1].

Latin America and Middle East & Africa

Latin America and the Middle East & Africa also hold a share of the global market, with CAGRs of 3.4% and 3.7%, respectively. These regions are experiencing growth due to improving healthcare infrastructure and increasing awareness of cardiovascular health[1].

Key Drivers of Market Growth

Increasing Prevalence of Cardiovascular Diseases

The rising incidence of cardiovascular diseases is a primary driver of the esmolol hydrochloride market. As the global population ages and lifestyles become more sedentary, the burden of heart-related conditions increases, driving the demand for effective treatments like esmolol hydrochloride[1][5].

Growing Demand for Effective Treatments

Healthcare providers are seeking rapid-response treatments for conditions such as supraventricular tachycardia and non-compensatory sinus tachycardia. Esmolol hydrochloride's quick-acting properties make it a preferred choice, thus increasing its utilization in clinical settings[1].

Intraoperative and Postoperative Tachycardia

The growing occurrence of intraoperative and postoperative tachycardia is another significant driver. Healthcare professionals prioritize effective management of heart rate fluctuations during and after surgical procedures, further boosting the demand for esmolol hydrochloride[1].

Competitive Landscape

The esmolol hydrochloride market is characterized by a competitive landscape with several key players. Companies such as Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., and Aurobindo Pharma Ltd. are prominent in the market. These companies are adopting strategies like mergers and acquisitions, product launches, and geographical expansion to strengthen their market presence[5].

Research and Development

Pharmaceutical companies are investing heavily in research and development to enhance the efficacy and safety of esmolol hydrochloride. Efforts are focused on developing novel formulations with improved patient compliance and reduced side effects. Collaborations and partnerships between pharmaceutical companies and research institutions are also driving product development and market expansion[5].

Financial Trajectory

Revenue Growth

The global esmolol hydrochloride market is expected to see significant revenue growth, driven by the increasing demand for effective cardiovascular treatments. The market size is projected to expand from its current value to a substantial figure by 2031, with a steady CAGR of 4.0% to 4.8% over the forecast period[1][5].

Regional Revenue

North America, being the dominant region, will continue to contribute significantly to the global revenue. The Asia-Pacific region, however, is expected to make substantial gains, driven by its high CAGR and growing healthcare expenditure[1].

Challenges and Opportunities

Cost Management

One of the challenges faced by the market is the management of costs associated with the drug. Similar to other pharmaceuticals, such as isoproterenol, cost increases can significantly impact hospital budgets. Implementing strategies to mitigate these costs, such as drug use evaluations and operational efficiencies, is crucial[3].

Market Expansion

The increasing geriatric population and changing lifestyles present opportunities for market expansion. Pharmaceutical companies can leverage these trends by focusing on innovation and strategic partnerships to develop advanced treatment options for cardiovascular diseases[5].

Key Takeaways

• The global esmolol hydrochloride market is expected to grow at a CAGR of 4.0% to 4.8% from 2024 to 2031.
• North America currently dominates the market, but the Asia-Pacific region is expected to witness the highest growth.
• The increasing prevalence of cardiovascular diseases and the growing demand for effective treatments are key drivers of the market.
• Pharmaceutical companies are focusing on research and development to enhance the efficacy and safety of esmolol hydrochloride.
• The competitive landscape is characterized by key players adopting strategies such as mergers and acquisitions, product launches, and geographical expansion.

FAQs

What is the projected CAGR for the global esmolol hydrochloride market from 2024 to 2031?

The global esmolol hydrochloride market is expected to expand at a CAGR of 4.0% from 2024 to 2031[1].

Which region is expected to witness the highest growth in the esmolol hydrochloride market?

The Asia-Pacific region is anticipated to witness the highest growth, with a CAGR of 6.0% from 2024 to 2031[1].

What are the primary drivers of the esmolol hydrochloride market?

The increasing prevalence of cardiovascular diseases and the growing demand for effective treatments are primary drivers of the market[1][5].

Who are the key players in the esmolol hydrochloride market?

Key players include Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., and Aurobindo Pharma Ltd.[5].

What strategies are pharmaceutical companies adopting to strengthen their market presence?

Pharmaceutical companies are adopting strategies such as mergers and acquisitions, product launches, and geographical expansion to strengthen their market presence[5].

Sources

1. Cognitive Market Research: Esmolol Hydrochloride Market Report 2024 (Global Edition)[1].
2. BioSpace: Correvio Reports First Quarter 2019 Financial Results[2].
3. ASHP Media: Administrative Practice/ Financial Management / Human Resources[3].
4. Allied Market Research: Esmolol Hydrochloride Market[4].
5. MarkWide Research: Esmolol Hydrochloride Market Poised for Steady Growth with a Projected CAGR of 4.8% by 2030[5].